# US 2015/0147320 A1 · Ophthalmic Drug Delivery System Containing Phospholipid and Cholesterol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147320 A1
- Document ID: US20150147320A1
- Status: Published application
- Kind: A1
- Application number: 14/572,062
- Filed: 2014-12-16
- Published: 2015-05-28
- Earliest claimed: 2009-08-10
- Assignees: Taiwan Liposome Co., Ltd.; Tlc Biopharmaceuticals, Inc.
- Applicants: Taiwan Liposome Co. Ltd.; Tlc Biopharmaceuticals, Inc.
- Inventors: SHEUE-FANG SHIH; PO-CHUN CHANG; YUN-LONG TSENG; LUKE S.S. GUO; KEELUNG HONG
- Web page: https://patentgrep.com/patent/US20150147320A1

## CPC

- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/385: {Serum albumin}
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.

## Claims

### Claim 1

A drug delivery system, comprising
(a) a delivery vehicle containing cholesterol and a phospholipid or a mixture of a first phospholipid and a second phospholipid, wherein the first phospholipid is DOPC, POPC, SPC, or EPC and the second phospholipid is PEG-DSPE or DOPG, and the cholesterol is present in an amount of 5-40 mole percent relative to the delivery vehicle; and
(b) one or more therapeutic agent,
wherein 50-90% of the therapeutic agent is in non-associated form and the weight ratio of the phospholipid and cholesterol in combination to the therapeutic agent is 5-80 to 1.

### Claim 2 (depends on 1)

The drug delivery system of claim 1, wherein the therapeutic agent is an antagonist specific to VEGF.

### Claim 3 (depends on 2)

The drug delivery system of claim 2, wherein the antagonist specific to VEGF is an antibody specific to VEGF, a VEGF receptor, a nucleic acid, a peptide or a small molecule.

### Claim 4 (depends on 3)

The drug delivery system of claim 3, wherein the antibody specific to VEGF is a naturally occurring immunoglobulin, a functional fragment thereof, a humanized antibody, a chimeric antibody, a diabody or a single chain antibody.

### Claim 5 (depends on 3)

The drug delivery system of claim 3, wherein, the antibody specific to VEGF is Avastin.

### Claim 6 (depends on 3)

The drug delivery system of claim 3, wherein the antibody specific to VEGF is a Fab, Fab′, F(ab)2 or F(ab′)2 fragment.

### Claim 7 (depends on 1)

The drug delivery system of claim 1, wherein the therapeutic agent is an anti-inflammation molecule.

### Claim 8 (depends on 7)

The drug delivery system of claim 7, wherein the anti-inflammation molecule is a corticosteroid.

### Claim 9 (depends on 1)

The drug delivery system of claim 1, wherein the delivery vehicle and the therapeutic agent are admixed and in lyophilized form.

### Claim 10 (depends on 1)

The drug delivery system of claim 1, wherein the delivery vehicle and the therapeutic agent for the eye are separate.

### Claim 11 (depends on 10)

The drug delivery system of claim 10, wherein the delivery vehicle is in lyophilized form.

### Claim 12 (depends on 1)

The drug delivery system of claim 1, wherein 60-90% of the therapeutic agent is in non-associated form and the weight ratio of the phospholipid and cholesterol in combination to the therapeutic agent is 5-40 to 1.

### Claim 13 (depends on 1)

The drug delivery system of claim 1, wherein the first phospholipid is DOPC and the second phospholipid is DOPG.

### Claim 14 (depends on 1)

The drug delivery system of claim 1, wherein the first phospholipid is POPC and the second phospholipid is PEG-DSPE or DOPG.

### Claim 15 (depends on 1)

The drug delivery system of claim 1, wherein the first phospholipid is SPC and the second phospholipid is PEG-DSPE.

### Claim 16 (depends on 1)

The drug delivery system of claim 1, wherein the first phospholipid is EPC and the second phospholipid is PEG-DSPE.

### Claim 17 (depends on 13)

The drug delivery system of claim 13, wherein the mole percent of DOPC is 29.5% to 90% and the mole percent of DOPG is 3% to 37.5% relative to the delivery vehicle.

### Claim 18 (depends on 13)

The drug delivery system of claim 13, wherein the mole percent of DOPC is 56.25-72.5% and the mole percent of DOPG is 7.5-18.75 relative to the delivery vehicle.

### Claim 19 (depends on 1)

The drug delivery system of claim 1, wherein the mole percent of cholesterol is 10-33% relative to the delivery vehicle.

### Claim 20 (depends on 1)

The drug delivery system of claim 1, wherein the mole percent of cholesterol is 20-25% relative to the delivery vehicle.
